TDC
MCRB icon

Thompson Davis & Co’s Seres Therapeutics MCRB Stock Holding History

Thompson Davis & Co’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-6
Closed -$2K – 1168
2016
Q3 		$2K Buy
+6
New +$2.1K ﹤0.01% 1007

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Thompson Davis & Co's MCRB Position: Q4 2016 in Review

Thompson Davis & Co sold out of Seres Therapeutics (MCRB) in Q4 2016, closing a stake of 6 shares — an estimated $2K sold.

Thompson Davis & Co first reported a position in MCRB in Q3 2016 and held it in 1 quarter. The position peaked at $2K in Q3 2016. 89 funds tracked by Wall St. Rank hold MCRB as of Q4 2016.

  • Thompson Davis & Co reported no remaining Seres Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Thompson Davis & Co sold 6 Seres Therapeutics shares in Q4 2016, an estimated $2K.
  • Thompson Davis & Co first reported a position in Seres Therapeutics in Q3 2016 and held it in 1 quarter.
  • Thompson Davis & Co's Seres Therapeutics position peaked at $2K in Q3 2016.
  • 89 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2016.

Based on Thompson Davis & Co's 13F filing for Q4 2016, filed 7 Feb 2017.